Compare BIO-TECHNE Corp (TECH) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs TransMedics Group Inc — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: BIO-TECHNE Corp is far larger — about 4.4× TransMedics Group Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TECH | TMDX | |
|---|---|---|
Market Cap | $11.16B | $2.54B |
Sector | Health | Technology |
52-Week High | $72.12 | $150.42 |
52-Week Low | $43.31 | $61.99 |
Enterprise Value | $11.24B | $2.94B |
Dividend Yield | 0.45% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
